News
A new weight loss drug that's being trialled as a daily pill and could rival Ozempic has delivered some astonishing results.
Ozempic, originally for type 2 diabetes, has surged in popularity in North America as a weight-loss solution, sparking a ...
Topiramate, also sold under the brand name Topamax, is a drug approved by the U.S. Food and Drug Administration (FDA) for ...
A federal judge rejected a bid by compounding pharmacies to continue selling versions of weight-loss drug Wegovy and diabetes ...
In 2024, the U.S. healthcare industry spent $6.1 billion on Pfizer’s COVID-19 therapy Paxlovid, a 6,922.8% increase from 2023 expenditure data, according to a recent study. The research, published ...
Novo Nordisk faces a suit claiming it failed to warn users of Ozempic of the danger of blindness. The suit is brought by a ...
College of Charleston's Kindred Hurtado examines one woman's weight-loss journey with the assistance of semaglutides.
Eli Lilly's Orforglipron shines in Phase III trials, potentially leading diabetes and obesity treatment by 2026. See what to ...
Patients flocked to those Ozempic, Wegovy copycats when the branded drugs were in short supply, or if they didn’t have ...
Zepbound (tirzepatide) is a weekly injectable weight-loss medication. It can be purchased online or in person with a valid ...
The pecking order of the obesity drug market is shifting. Eli Lilly , the $815 billion maker of blockbuster weight-loss drugs ...
One such example is Novo Nordisk ( NVO 2.01%), the Denmark-based pharmaceutical leader whose shares are exchanging hands for just $60 each, and as recently as last July, traded in the mid-140s. Novo ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results